Article Text
Letter
Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis: a proof-of-concept study
Footnotes
Contributors Study design: RW, PC, BL, GV, FVdB, DE. Data collection: RW, PM, BL. Data analysis: RW. Data interpretation: RW, BL, PC, FVdB, DE. Writing of the report: RW. All authors approved the final version of the manuscript.
Funding This work concerns an investigator-initiated study supported by UCB Pharma.
Competing interests None.
Patient consent Obtained.
Ethics approval Ethics Committee of Ghent University Hospital, Belgium.
Provenance and peer review Not commissioned; externally peer reviewed.